SAN DIEGO, July 25 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. , a biopharmaceutical company committed to the discovery, development and commercialization of novel small molecule medicines for the treatment of viral diseases and cancer announced today that it will report second quarter 2007 financial results on Wednesday, August 1, 2007 after the U.S. financial markets close.
Anadys will hold a conference call and webcast on Wednesday, August 1, 2007 at 5:00 p.m. Eastern Daylight Time (EDT) to discuss its second quarter financial results and operational highlights and to give an update on its programs and product candidate portfolio. To access the webcast via the Internet, log on to http://www.anadyspharma.com. A telephone replay will be available approximately one hour after completion of the conference call. To access the telephone replay, dial (888) 286-8010 (domestic) or (617) 801-6888 (international), passcode 82775800. The webcast and telephone replay will be available through August 15, 2007.
About Anadys
Anadys Pharmaceuticals, Inc., http://www.anadyspharma.com, is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of viral diseases and cancer. The Company’s programs focus on Toll- Like Receptor-based small molecule product candidates and direct antiviral compounds that inhibit key steps in viral proliferation. The Company has core expertise in medicinal chemistry coupled with structure-based drug design, and is developing compounds for the treatment of hepatitis C infection, hepatitis B infection and cancer.
Safe Harbor Statement
Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys’ actual results to be materially different from historical results or from any results expressed or implied by such forward- looking statements. Risk factors that may cause actual results to differ are discussed in Anadys’ SEC filings, including Anadys’ Form 10-K for the year ended December 31, 2006 and the “Risk Factors” section of Anadys’ Form 10-Q for the quarter ended March 31, 2007. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
Anadys Pharmaceuticals, Inc.
CONTACT: James T. Glover, Senior Vice President, Operations & ChiefFinancial Officer of Anadys Pharmaceuticals, Inc., +1-858-530-3763,jglover@anadyspharma.com
Web site: http://www.anadyspharma.com//
